75% disease control observed in CHM CDH17 trial

Sydney, Australia, 13 November 2025: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce it has achieved continued disease control and tumour shrinkage in its CHM CDH17 Phase 1/2 clinical trial. Four study subjects have been treated at Dose Level 2, with all achieving stable disease per the RECIST 1.1 Criteria as part of their